Future research should focus on addressing key challenges, including targeted delivery of STING agonists to tumor tissues, precise modulation of STING activity at different stages of disease progression, cell-type specific targeting, and strategies for fine-tuning STING activation levels to maximize therapeutic benefit and minimize potential adverse effects. This evidence concerns the gene STING1 and neoplasm.